ITP Treatment Considerations

Videos require an HTML5 capable browser or Flash Player 9+.

Get Adobe Flash Player

Platelet counts lower than normal but > 50 x 109/L are usually discovered incidentally.[11] Once platelet counts are < 50 x 109/L, the risk for bleeding events increases.[11][17] Following are symptoms and risks associated with specific platelet levels:

Symptoms and risks of ITP (12,18)

Have questions about ITP treatment considerations? Talk with a live representative

Review on a case-by-case basis, and consider the potential for spontaneous improvement or late remission, which may occur 6 to 12 months or even years after diagnosis.[8][9][16]*

Spontaneous Remission

Assess when treatment is needed

Experts indicate that the decision to treat should be based on platelet count (< 30 x 109/L, per the American Society of Hematology ITP guideline) and/or other considerations, such as [9][16]:

  • Severity of bleeding
  • Risk factors for bleeding
  • Activity level
  • Possible treatment side effects
  • Patient preferences
According to the experts, their recommendations are intended as guides only and should not supersede the physician’s judgment based on the patient’s specific needs and preferences.[9][16]

Have questions about ITP treatment considerations?

Talk with a Live Representative



Nplate® is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.

Nplate® is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than chronic ITP. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.


Risk of Progression of Myelodysplastic Syndromes to Acute Myelogenous Leukemia

  • In Nplate® clinical trials of patients with myelodysplastic syndromes (MDS) and severe thrombocytopenia, progression from MDS to acute myelogenous leukemia (AML) has been observed.
  • Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP.

Thrombotic/Thromboembolic Complications

  • Thrombotic/thromboembolic complications may result from increases in platelet counts with Nplate® use. Portal vein thrombosis has been reported in patients with chronic liver disease receiving Nplate®.
  • To minimize the risk for thrombotic/thromboembolic complications, do not use Nplate® in an attempt to normalize platelet counts. Follow the dose adjustment guidelines to achieve and maintain a platelet count of ≥ 50 x 109/L.

Loss of Response to Nplate®

  • Hyporesponsiveness or failure to maintain a platelet response with Nplate® should prompt a search for causative factors, including neutralizing antibodies to Nplate®.
  • To detect antibody formation, submit blood samples to Amgen (1-800-772-6436). Amgen will assay these samples for antibodies to Nplate® and thrombopoietin (TPO).
  • Discontinue Nplate® if the platelet count does not increase to a level sufficient to avoid clinically important bleeding after 4 weeks at the highest weekly dose of 10 mcg/kg.

Laboratory Monitoring

  • Obtain CBCs, including platelet counts, weekly during the dose adjustment phase of Nplate® therapy and then monthly following establishment of a stable Nplate® dose.
  • Obtain CBCs, including platelet counts, weekly for at least two weeks following discontinuation of Nplate®.

Adverse Reactions

  • In the placebo-controlled trials, headache was the most commonly reported adverse drug reaction, occurring in 35% of patients receiving Nplate® and 32% of patients receiving placebo. Headaches were usually of mild or moderate severity.
  • Most common adverse reactions (≥ 5% higher patient incidence in Nplate® versus placebo) were Arthralgia (26%, 20%), Dizziness (17%, 0%), Insomnia (16%, 7%), Myalgia (14%, 2%), Pain in Extremity (13%, 5%), Abdominal Pain (11%, 0%), Shoulder Pain (8%, 0%), Dyspepsia (7%, 0%), and Paresthesia (6%, 0%).
  • Nplate® administration may increase the risk for development or progression of reticulin fiber formation within the bone marrow. This formation may improve upon discontinuation of Nplate®. In a clinical trial, one patient with ITP and hemolytic anemia developed marrow fibrosis with collagen during Nplate® therapy.

Please see Prescribing Information and Medication Guide

Have questions about the Indication, Important Safety Information, Prescribing Information or Medication Guide?

Talk with a Live Representative


Helps your eligible commercially insured patients who are appropriate for Nplate® treatment reduce their out-of-pocket costs.

Learn How To Enroll Your Practice


Clinical studies have evaluated Nplate® for the treatment of adult patients with chronic ITP. Nplate® clinical trials have been conducted in both splenectomized and non-splenectomized patients.

Review Nplate® Clinical Data


Get answers from one of our representatives.

Find Out More

Amgen Nplate® is a registered trademark of Amgen, Inc. © 2014 Amgen Inc. All Rights Reserved. 60499-R12-V1 For US Healthcare Professionals Only.

Talk with a live representative Email this